We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Treatment of Androgenetic Alopecia in Females, 12 Beam

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01016964
Recruitment Status : Completed
First Posted : November 20, 2009
Results First Posted : September 7, 2012
Last Update Posted : September 7, 2012
Information provided by (Responsible Party):
Lexington International, LLC

Brief Summary:
The purpose of this study is to evaluate the efficacy of the HairMax LaserComb 2009 12 beam model for androgenetic alopecia in females when treatment is applied as directed.

Condition or disease Intervention/treatment Phase
Androgenetic Alopecia Hair Loss Female Pattern Baldness Device: HairMax LaserComb 2009 model 12 beam Device: Sham Device Not Applicable

Detailed Description:

This is a randomized double-blind, sham controlled clinical study, evaluating changes in terminal hair count in the evaluation zone having evidence of androgenetic alopecia (miniaturized hair).

The trial with 63 female subjects, who have been diagnosed with androgenetic alopecia, who are between 25 and 60 years of age, have Fitzpatrick Skin Types I-IV, with classifications of Ludwig I-4, II-1, II-2, or frontal, have active hair loss within the last 12 months.

Subjects will use the device on three non-concurring days a week as directed per device for 26 weeks duration.

Initial efficacy endpoint for each subject will be assessed at visit 4 (week 16).

Safety analysis will be assessed based on the reports of adverse events during study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 63 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind Clinical Trial to Evaluate the Safety and Efficacy of the HairMax LaserComb 2009, 12 Beam Model For The Treatment of Androgenetic Alopecia in Females
Study Start Date : January 2010
Actual Primary Completion Date : March 2011
Actual Study Completion Date : March 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Sham Comparator: Sham Device
Sham device
Device: Sham Device
Sham Device

Active Comparator: LLT Device 2009 12 Beams
HairMax LaserComb 2009 model 12 beam
Device: HairMax LaserComb 2009 model 12 beam
HairMax LaserComb

Primary Outcome Measures :
  1. Change in Hair Count at 16 and 26 Weeks Over Baseline [ Time Frame: Baseline, 16 weeks, 26 weeks ]
    The primary analysis of effectiveness was an analysis of covariance, which separately modeled terminal hair count at Week 16 and Week 26 as a function of treatment group (HairMax LaserComb 2009 9 Beam vs.control), study center, age (as a continuous variable), and Fitzpatrick Skin Type classification (as a categorical variable with four levels). The active group was compared to the control device using least squares means with a two-sided test at the 5% level of significance.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   25 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Diagnosis of androgenetic alopecia
  • Fitzpatrick Skin types I-IV
  • Ludwig I-4, II-1, II-2, or frontal
  • Active hair loss within last 12 months

Exclusion Criteria:

  • Photosensitivity to laser light
  • Malignancy in the target area
  • Pregnancy
  • Lactating females

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01016964

Layout table for location information
United States, Florida
University of Miami Miller School of Medicine - Dermatology
Miami, Florida, United States, 33136
United States, Minnesota
University of Minnesota, Department of Dermatology
Minneapolis, Minnesota, United States, 55455
United States, Ohio
Cleveland Clinic Foundation - Department of Dermatology
Cleveland, Ohio, United States, 44195
Sponsors and Collaborators
Lexington International, LLC
Layout table for investigator information
Principal Investigator: Maria Hordinsky, M.D. University of Minnesota
Principal Investigator: Wilma Bergfeld, M.D. The Cleveland Clinic
Principal Investigator: Lawrence Schachner, M.D. University of Miami
Layout table for additonal information
Responsible Party: Lexington International, LLC
ClinicalTrials.gov Identifier: NCT01016964    
Obsolete Identifiers: NCT01042756
Other Study ID Numbers: 12 2009-F-02
First Posted: November 20, 2009    Key Record Dates
Results First Posted: September 7, 2012
Last Update Posted: September 7, 2012
Last Verified: August 2012
Keywords provided by Lexington International, LLC:
Androgenetic Alopecia
Hair Loss
Female Pattern Baldness
Additional relevant MeSH terms:
Layout table for MeSH terms
Alopecia Areata
Hair Diseases
Skin Diseases
Pathological Conditions, Anatomical